Treatment of inclusion body myositis with adipose-derived regenerative cells

Abstract

A method for treating inclusion body myositis (IBM) in a subject can include: providing a subject that has IBM; obtaining adipose-derived regenerative cells (ADRC); and administering the ADRC to the subject to treat the IBM. The ADRCs can be obtained by a closed system for use as the therapeutic as described herein. The ADRCs can be obtained in a system that can then be used for providing the ADRCs for administration. The system can be automated and may provide the ADRCs in sufficient purity for reimplantation. The method can include: injecting the ADRC as cells into one injection location or a plurality of injection locations to provide at least a million cells, more preferably at least 10 million cells, even more preferably at least 20 million cells, or most preferably at least 30 million cells.

Dependencies are inferred from the claim text.